Y-mAbs Therapeutics, Inc. (YMAB)
Sep 15, 2025 - YMAB was delisted (reason: acquired by SERB Pharmaceuticals)
8.61
+0.02 (0.23%)
Inactive · Last trade price
on Sep 15, 2025
Y-mAbs Therapeutics Employees
Y-mAbs Therapeutics had 104 employees as of December 31, 2024. The number of employees increased by 4 or 4.00% compared to the previous year.
Employees
104
Change (1Y)
4
Growth (1Y)
4.00%
Revenue / Employee
$821,010
Profits / Employee
-$213,692
Market Cap
391.22M
Employees Chart
YMAB News
- 3 months ago - Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - GlobeNewsWire
- 4 months ago - Y-mAbs (YMAB) Q2 Revenue Falls 14% - The Motley Fool
- 4 months ago - Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 4 months ago - Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB - Business Wire
- 4 months ago - Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025 - GlobeNewsWire
- 4 months ago - SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics - GlobeNewsWire
- 6 months ago - Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - GlobeNewsWire
- 6 months ago - Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - GlobeNewsWire